Cargando…
Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354303/ https://www.ncbi.nlm.nih.gov/pubmed/32676378 http://dx.doi.org/10.21037/tau-20-837 |
| _version_ | 1783558055403716608 |
|---|---|
| author | Koga, Fumitaka |
| author_facet | Koga, Fumitaka |
| author_sort | Koga, Fumitaka |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7354303 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73543032020-07-15 Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer? Koga, Fumitaka Transl Androl Urol Editorial Commentary AME Publishing Company 2020-06 /pmc/articles/PMC7354303/ /pubmed/32676378 http://dx.doi.org/10.21037/tau-20-837 Text en 2020 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Koga, Fumitaka Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer? |
| title | Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer? |
| title_full | Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer? |
| title_fullStr | Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer? |
| title_full_unstemmed | Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer? |
| title_short | Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer? |
| title_sort | will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354303/ https://www.ncbi.nlm.nih.gov/pubmed/32676378 http://dx.doi.org/10.21037/tau-20-837 |
| work_keys_str_mv | AT kogafumitaka willchemoradiationbasedbladdersparingtherapybecomeastandardofcareformuscleinvasivebladdercancer |